FDA approves Gilead's injection Yeztugo for HIV prevention, offering convenience and potential game-changing impact

From CNBC: 2025-06-18 14:47:00

The FDA approved Gilead’s twice-yearly antiviral injection for HIV prevention, marking a milestone in the fight against the epidemic. The injectable drug, Yeztugo, has shown promise in eliminating new infections. With 1.3 million new infections globally in 2023, the drug’s convenience could be a game-changer. HIV disproportionately affects people of color and LGBTQ+ communities.

Yeztugo, priced at $28,218 annually, offers a more convenient option compared to existing daily pills. Gilead is committed to making the injection accessible through copay savings programs and free doses for the uninsured. Analysts project peak sales of $4 billion globally. Gilead also granted licenses to produce lower-cost versions in low-income countries.

Stigma and cultural challenges have hindered HIV prevention efforts. Gilead’s injection, proven 99.9% effective in trials, could provide privacy and convenience. With 39% of new HIV diagnoses in Black Americans, increasing awareness and access to the injection is crucial. Proposed GOP funding cuts threaten Medicaid coverage for HIV treatment and prevention.

Ensuring access to underserved populations and expanding insurance coverage are critical for reaching lower-income communities. Medicaid covers 40% of nonelderly adults with HIV in the U.S. Proposed federal funding cuts could jeopardize HIV prevention programs. Advocates warn that without pushback from Congress, HIV prevention efforts could suffer, leading to increased infections.



Read more at CNBC: FDA approves Gilead HIV prevention injection lenacapavir